These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 35863024)

  • 1. Nitrite Promotes ROS Production to Potentiate Cefoperazone-Sulbactam-Mediated Elimination to Lab-Evolved and Clinical-Evolved Pseudomonas aeruginosa.
    Kuang SF; Li X; Feng DY; Wu WB; Li H; Peng B; Peng XX; Chen ZG; Zhang TT
    Microbiol Spectr; 2022 Aug; 10(4):e0232721. PubMed ID: 35863024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inactivation of Nitrite-Dependent Nitric Oxide Biosynthesis Is Responsible for Overlapped Antibiotic Resistance between Naturally and Artificially Evolved Pseudomonas aeruginosa.
    Kuang SF; Feng DY; Chen ZG; Liang ZZ; Xiang JJ; Li H; Peng XX; Zhang T
    mSystems; 2021 Oct; 6(5):e0073221. PubMed ID: 34546070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucose-Potentiated Amikacin Killing of Cefoperazone/Sulbactam Resistant
    Tang XK; Su YB; Ye HQ; Dai ZY; Yi H; Yang KX; Zhang TT; Chen ZG
    Front Microbiol; 2021; 12():800442. PubMed ID: 35310395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repressed Central Carbon Metabolism and Its Effect on Related Metabolic Pathways in Cefoperazone/Sulbactam-Resistant
    Chen YT; Yang KX; Dai ZY; Yi H; Peng XX; Li H; Chen ZG
    Front Microbiol; 2022; 13():847634. PubMed ID: 35308347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amikacin and cefoperazone/sulbactam alone or in combination against carbapenem-resistant Pseudomonas aeruginosa.
    Cai Y; Yang D; Wang J; Wang R
    Diagn Microbiol Infect Dis; 2018 Jun; 91(2):186-190. PubMed ID: 29486972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual Effect: High NADH Levels Contribute to Efflux-Mediated Antibiotic Resistance but Drive Lethality Mediated by Reactive Oxygen Species.
    Arce-Rodríguez A; Pankratz D; Preusse M; Nikel PI; Häussler S
    mBio; 2022 Feb; 13(1):e0243421. PubMed ID: 35038918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergy of gatifloxacin with cefoperazone and cefoperazone-sulbactam against resistant strains of Pseudomonas aeruginosa.
    Sivagurunathan N; Krishnan S; Rao JV; Nagappa AN; Subrahmanyam VM; Vanathi BM
    J Med Microbiol; 2008 Dec; 57(Pt 12):1514-1517. PubMed ID: 19018022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential Proteomic and Genomic Comparison of Resistance Mechanism of Pseudomonas aeruginosa to Cefoperazone Sodium/Sulbactam Sodium.
    Cai S; Zhang K; Wei F; Yang L; Song D; Luo J; Huang H; Gao X; DU G; Kong J; Chen Y
    An Acad Bras Cienc; 2022; 94(3):e20211160. PubMed ID: 36074406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In-vitro activity of cefoperazone-sulbactam combination against cefoperazone resistant clinical isolates in a Malaysian general hospital.
    Lim VK; Cheong YM
    Malays J Pathol; 1995 Dec; 17(2):73-6. PubMed ID: 8935129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cefoperazone/sulbactam: New composites against multiresistant gram negative bacteria?
    Ku YH; Yu WL
    Infect Genet Evol; 2021 Mar; 88():104707. PubMed ID: 33418147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of inoculum size on the activity of cefoperazone-sulbactam against multidrug resistant organisms.
    Chang PC; Chen CC; Lu YC; Lai CC; Huang HL; Chuang YC; Tang HJ
    J Microbiol Immunol Infect; 2018 Apr; 51(2):207-213. PubMed ID: 29037802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Changes of antimicrobial resistance among nonfermenting gram-negative bacilli isolated from intensive care units from 1994 to 2001 in China].
    Wang H; Chen MJ;
    Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):385-90. PubMed ID: 12820914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-vitro susceptibility of cefoperazone-susceptible and -resistant gram-negative rods to cefoperazone plus sulbactam, other beta-lactams, aminoglycosides and quinolone.
    Chandrasekar PH; Sluchak JA
    Infection; 1991; 19(1):49-53. PubMed ID: 2013510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Error rates in cefoperazone and cefoperazone-sulbactam disk tests with Enterobacteriaceae and Pseudomonas aeruginosa.
    Hardy DJ; Barry AL; Fuchs PC; Gerlach EH; McLaughlin JC; Pfaller MA
    Eur J Clin Microbiol Infect Dis; 1992 Oct; 11(10):926-30. PubMed ID: 1486889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of cefoperazone/sulbactam in critically ill patients receiving continuous venovenous hemofiltration.
    Gao C; Tong J; Yu K; Sun Z; An R; Du Z
    Eur J Clin Pharmacol; 2016 Jul; 72(7):823-30. PubMed ID: 27023465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Memantine Promotes Bactericidal Effect of Neutrophils Against Infection with
    Xiao Y; Zhang TS; Li YH; Liu CF; Yang SJ; Zeng LT; Huang SH; Deng XY; Peng L
    Microb Drug Resist; 2022 Jan; 28(1):7-17. PubMed ID: 34357802
    [No Abstract]   [Full Text] [Related]  

  • 17. In vitro activity of cefoperazone-sulbactam combinations against cefoperazone-resistant clinical bacterial isolates.
    Eliopoulos GM; Klimm K; Ferraro MJ; Moellering RC
    Eur J Clin Microbiol Infect Dis; 1989 Jul; 8(7):624-6. PubMed ID: 2506024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Analysis of drug resistance of Pseudomonas aeruginosa and use of antibiotics in burn wards during 6 years].
    Dou Y; Zhang Q
    Zhonghua Shao Shang Za Zhi; 2014 Feb; 30(1):9-14. PubMed ID: 24684983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical experience with the treatment of severe nosocomial infections by inhibitor-protected 3rd generation cephalosporin cefoperazone/sulbactam].
    Beloborodova NV; Kuznetsova ST; Popov DA; Bachinskaia EN; Vostrikov TIu
    Antibiot Khimioter; 2005; 50(4):33-40. PubMed ID: 16392338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral streptococci and nitrite-mediated interference of Pseudomonas aeruginosa.
    Scoffield JA; Wu H
    Infect Immun; 2015 Jan; 83(1):101-7. PubMed ID: 25312949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.